Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar (pic) said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.
KUALA LUMPUR: Malaysia’s global leadership in setting standards for halal pharmaceuticals has served to facilitate the successful entry of domestic pharmaceutical manufacturers into the international halal pharmaceutical market, which is forecast to be valued at US$134bil by 2024.
Duopharma Biotech Bhd
group managing director Leonard Ariff Abdul Shatar said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
